Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Rhea-AI Summary
Anixa (NASDAQ: ANIX) announced that Dr. Robert Wenham of Moffitt Cancer Center will present an update on the company’s Phase 1 ovarian cancer CAR-T trial (lira-cel) at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, April 10–13, 2026 in San Juan, Puerto Rico.
The presentation will cover the trial design, objectives, and current status of the autologous T-cell therapy targeting FSHR in recurrent ovarian cancer.
Positive
- None.
Negative
- None.
News Market Reaction – ANIX
In the Mar 30 session, ANIX declined 1.96%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Breast vaccine data | Positive | -25.4% | Final Phase 1 breast cancer vaccine data with 74% immune response presented. |
| Oct 07 | Trial completion | Positive | +26.5% | Completion of final patient visit in Phase 1 breast cancer vaccine trial. |
| Sep 08 | CAR-T cohort dosed | Positive | +0.3% | Completion of dosing in fourth cohort of ovarian cancer CAR-T trial with survival benefit signals. |
| Aug 18 | CAR-T patient treated | Positive | +0.3% | Second patient treated in fourth CAR-T cohort at higher dose without dose-limiting toxicities. |
| Jun 23 | Cohort initiation | Positive | +3.3% | Initiation of dosing in fourth cohort of ovarian cancer CAR-T trial at 30-fold higher dose. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial news has usually led to positive price reactions, with 4 of 5 past clinical updates followed by gains, but one major divergence where strong Phase 1 breast cancer vaccine data coincided with a sharp selloff.
Over the past year, Anixa has steadily advanced its oncology pipeline, particularly the breast cancer vaccine and FSHR‑targeted ovarian cancer CAR‑T program. Multiple updates in 2025 highlighted dose escalation through the fourth cohort, encouraging survival signals, and completion of Phase 1 enrollment and follow-up in the breast cancer vaccine trial. Final vaccine data presented on Dec 11, 2025 showed primary endpoints met and immune responses in 74% of participants. Today’s conference presentation fits this pattern of ongoing clinical visibility rather than a new efficacy inflection point.
Key Terms
car-t therapy medical
autologous t cells medical
chimeric receptor medical
follicle-stimulating hormone receptor medical
fshr medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Robert
Dr.
The SGO Annual Meeting on Women's Cancer stands as the foremost educational and scientific gathering for professionals dedicated to the treatment and care of individuals with gynecologic cancer, bringing together global experts in gynecologic oncology to share the latest scientific advancements, participate in educational programs, and network with peers.
About Lira-cel, Anixa's CAR-T Therapy for Recurrent Ovarian Cancer
Liraltagene autoleucel, or lira-cel, uniquely targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells, but not in healthy tissue. The ongoing Phase 1 trial (ClinicalTrials.gov NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-of-its-ovarian-cancer-car-t-therapy-clinical-trial-at-the-society-of-gynecologic-oncology-annual-meeting-on-womens-cancer-302728024.html
SOURCE Anixa Biosciences, Inc.